Investors and Media

Investors and Media

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Corporate Profile

Corporate Presentation (December 2024)

Corporate Presentation (December 2024)

Dec 2, 2024

Dec 2, 2024

ASX Announcements

Placement Shares Cleansing Notice 12 Dec 2024

Placement Shares Cleansing Notice 12 Dec 2024

Dec 12, 2024

Dec 12, 2024

Application for quotation of securities 12 Dec 24

Application for quotation of securities 12 Dec 24

Dec 12, 2024

Dec 12, 2024

FDA Grants Fast Track Designation

FDA Grants Fast Track Designation

Dec 9, 2024

Dec 9, 2024

Proposed issue of securities - CMB

Proposed issue of securities - CMB

Dec 5, 2024

Dec 5, 2024

Cambium Bio Successfully Closes A$3.0M Financing Round

Cambium Bio Successfully Closes A$3.0M Financing Round

Dec 5, 2024

Dec 5, 2024

For all Cambium Bio Limited ASX market announcements, click here

Financial Information

Cambium Bio Limited Annual Report FY2024

Cambium Bio Limited Annual Report FY2024

Aug 30, 2024

Aug 30, 2024

Cambium Bio Limited Half Year Report (December 2023)

Cambium Bio Limited Half Year Report (December 2023)

Dec 31, 2023

Dec 31, 2023

Cambium Bio Limited Annual Report FY2023

Cambium Bio Limited Annual Report FY2023

Jun 30, 2023

Jun 30, 2023

News Releases

Regeneus trebles on back of merger deal (Sydney Morning Herald)

Regeneus trebles on back of merger deal (Sydney Morning Herald)

Apr 5, 2024

Apr 5, 2024

Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease

Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease

Feb 6, 2024

Feb 6, 2024

Events and Presentations

Meet Cambium Bio team at BIO International Convention in San Diego

Meet Cambium Bio team at BIO International Convention in San Diego

Apr 17, 2024

Apr 17, 2024